Analysis of Revenues
Paying user area
Try for free
Abbott Laboratories pages available for free this week:
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Profitability Ratios
- Analysis of Geographic Areas
- Common Stock Valuation Ratios
- Enterprise Value to FCFF (EV/FCFF)
- Return on Equity (ROE) since 2005
- Return on Assets (ROA) since 2005
- Price to Earnings (P/E) since 2005
- Price to Operating Profit (P/OP) since 2005
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Abbott Laboratories for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Revenues as Reported
Abbott Laboratories, income statement, revenues
US$ in millions
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
- Established Pharmaceutical Products
- The revenue from established pharmaceutical products shows a consistent upward trend over the period analyzed. Starting at $4,303 million in 2020, it rises steadily each year, reaching $5,194 million by 2024. This indicates sustained growth in this segment with moderate but continuous increases annually.
- Nutritional Products
- Nutritional products exhibit some fluctuations. Revenue increased from $7,647 million in 2020 to $8,294 million in 2021, followed by a decline to $7,459 million in 2022. The revenue then recovers and grows again to $8,154 million in 2023 and $8,413 million in 2024. The general pattern suggests variability but overall stability with a tendency towards growth in the later years.
- Diagnostic Products
- The diagnostic products segment experiences significant volatility. After a strong increase from $10,805 million in 2020 to $16,584 million in 2022, revenue sharply declines in the following years, falling to $9,988 million in 2023 and further down to $9,341 million in 2024. This indicates potential challenges or restructuring, resulting in a notable revenue contraction after peaking in 2022.
- Medical Devices
- Medical devices demonstrate robust growth throughout the period. Revenues rise from $11,787 million in 2020 to $18,986 million by 2024, with consistent annual increases. This segment appears to be a strong driver of overall revenue growth, reflecting increasing market demand or successful expansion initiatives.
- Reportable Segments
- Total revenue from reportable segments increases significantly from $34,542 million in 2020 to a peak of $43,642 million in 2022. However, this is followed by a decline to $40,095 million in 2023 and a slight recovery to $41,934 million in 2024. The overall trend suggests that after strong growth early in the period, the company faced some headwinds impacting total segment revenue.
- Other
- The category labeled as Other shows minimal and fluctuating revenues, ranging from $66 million in 2020 to a low of $11 million in 2022, and then modest increases to $16 million in 2024. Given the small scale, this segment has a negligible impact on total revenue.
- Net Sales to External Customers
- Net sales to external customers mirror the trend in reportable segments closely, rising from $34,608 million in 2020 to $43,653 million in 2022, followed by a decline in the subsequent years to $40,109 million in 2023 and mild recovery to $41,950 million in 2024. This alignment confirms that most sales come from the defined reportable segments, with an observable peak in 2022 and some deceleration thereafter.